Table 2 Secondary efficacy and safety outcomes.
Groups | No. of studies | Estimates | 95% CI | p-value for OE | I 2, % | p-value for heterogeneity | Q-value |
|---|---|---|---|---|---|---|---|
Secondary efficacy outcomes | SMD | ||||||
Length of hospital stay | 8 | −0.58 | −0.96–−0.19 | <0.01 | 89.7 | <0.01 | 68.09 |
IRCs | RR | ||||||
Pulmonary infection | 5 | 0.81 | 0.40–1.64 | 0.56 | 0.00 | 0.50 | 3.34 |
Urinary tract infection | 3 | 0.82 | 0.11–5.90 | 0.85 | 50.3 | 0.13 | 4.02 |
Deep vein thrombosis | 1 | 3.48 | 0.14–83.83 | 0.44 | None | None | None |
Pulmonary embolism | 1 | 0.23 | 0.01–5.35 | 0.36 | None | None | None |
Secondary safety outcomes | |||||||
Neurological deterioration | 4 | 0.79 | 0.39–1.60 | 0.52 | 57.9 | 0.07 | 7.13 |
Falls | 3 | 0.91 | 0.53–1.55 | 0.73 | 5.7 | 0.35 | 2.12 |
